Published in J Antimicrob Chemother on April 01, 1983
An overview of nosocomial infections, including the role of the microbiology laboratory. Clin Microbiol Rev (1993) 8.03
Molecular genetic analysis of cephalosporinase production and its role in beta-lactam resistance in clinical isolates of Enterobacter cloacae. Antimicrob Agents Chemother (1987) 1.39
Emergence of antibiotic resistance during therapy for infections caused by Enterobacteriaceae producing AmpC beta-lactamase: implications for antibiotic use. Antimicrob Agents Chemother (2007) 1.28
Cephamycin inactivation due to enzymatic hydrolysis by beta-lactamase from Bacteroides fragilis. Antimicrob Agents Chemother (1985) 0.92
Protective effect of amdinocillin against emergence of resistance to ceftazidime in Enterobacter cloacae. Antimicrob Agents Chemother (1988) 0.89
Epidemiological typing of Enterobacter aerogenes. J Clin Microbiol (1989) 0.86
Comparative study of the effects of ceftizoxime, piperacillin, and piperacillin-tazobactam concentrations on antibacterial activity and selection of antibiotic-resistant mutants of Enterobacter cloacae and Bacteroides fragilis in vitro and in vivo in mixed-infection abscesses. Antimicrob Agents Chemother (2004) 0.86
Mechanisms of resistance to cephalosporin antibiotics. Drugs (1987) 0.82
Comparison of a beta-lactamase induction test with a test that detects low-frequency resistance to cefotaxime. Antimicrob Agents Chemother (1985) 0.80
The changing ecology of hospital bacteria and the selective role of cephalosporins. Epidemiol Infect (1991) 0.78
Transient in vivo selection of a constitutively cephalosporin resistant Enterobacter cloacae causing ventriculitis. Can J Infect Dis (1995) 0.75
Clinical and microbiological characteristics of bloodstream infections due to AmpC β-lactamase producing Enterobacteriaceae: an active surveillance cohort in a large centralized Canadian region. BMC Infect Dis (2014) 0.75
Nitric oxide and macrophage function. Annu Rev Immunol (1997) 12.77
Cloning and characterization of inducible nitric oxide synthase from mouse macrophages. Science (1992) 9.01
Altered responses to bacterial infection and endotoxic shock in mice lacking inducible nitric oxide synthase. Cell (1995) 7.13
Macrophage deactivation by interleukin 10. J Exp Med (1991) 6.94
Role of transcription factor NF-kappa B/Rel in induction of nitric oxide synthase. J Biol Chem (1994) 6.91
Deactivation of macrophages by transforming growth factor-beta. Nature (1988) 5.56
Multiple antibiotic-resistant Klebsiella and Escherichia coli in nursing homes. JAMA (1999) 5.26
Activation of macrophages in vivo and in vitro. Correlation between hydrogen peroxide release and killing of Trypanosoma cruzi. J Exp Med (1979) 5.22
Strategies to Prevent and Control the Emergence and Spread of Antimicrobial-Resistant Microorganisms in Hospitals. A challenge to hospital leadership. JAMA (1996) 4.80
Inhibition of viral replication by interferon-gamma-induced nitric oxide synthase. Science (1993) 4.80
Phenotype of mice and macrophages deficient in both phagocyte oxidase and inducible nitric oxide synthase. Immunity (1999) 4.47
Promoter of the mouse gene encoding calcium-independent nitric oxide synthase confers inducibility by interferon gamma and bacterial lipopolysaccharide. J Exp Med (1993) 4.06
Reprogramming of the macrophage transcriptome in response to interferon-gamma and Mycobacterium tuberculosis: signaling roles of nitric oxide synthase-2 and phagocyte oxidase. J Exp Med (2001) 3.75
Inducible nitric oxide synthase in pulmonary alveolar macrophages from patients with tuberculosis. J Exp Med (1996) 3.74
Periplasmic superoxide dismutase protects Salmonella from products of phagocyte NADPH-oxidase and nitric oxide synthase. Proc Natl Acad Sci U S A (1997) 3.71
Peroxynitrite reductase activity of bacterial peroxiredoxins. Nature (2000) 3.69
Identification of arginine as a precursor of endothelium-derived relaxing factor. Proc Natl Acad Sci U S A (1988) 3.44
Contrasting mechanisms for suppression of macrophage cytokine release by transforming growth factor-beta and interleukin-10. J Biol Chem (1992) 3.18
Partner notification: can it control epidemic syphilis? Ann Intern Med (1990) 3.06
Colonization of skilled-care facility residents with antimicrobial-resistant pathogens. J Am Geriatr Soc (2001) 3.06
Mechanisms of suppression of macrophage nitric oxide release by transforming growth factor beta. J Exp Med (1993) 3.06
The role of "colonization pressure" in the spread of vancomycin-resistant enterococci: an important infection control variable. Arch Intern Med (1998) 2.94
Metabolic enzymes of mycobacteria linked to antioxidant defense by a thioredoxin-like protein. Science (2002) 2.89
Shedding of tumor necrosis factor receptors by activated human neutrophils. J Exp Med (1990) 2.80
Vancomycin-resistant enterococci in intensive-care hospital settings: transmission dynamics, persistence, and the impact of infection control programs. Proc Natl Acad Sci U S A (1999) 2.75
In vitro comparison of netilmicin, a semisynthetic derivative of sisomicin, and four other aminoglycoside antibiotics. Antimicrob Agents Chemother (1976) 2.75
Secretory leukocyte protease inhibitor: a macrophage product induced by and antagonistic to bacterial lipopolysaccharide. Cell (1997) 2.64
Transfusion-associated acquired immunodeficiency syndrome. Evidence for persistent infection in blood donors. N Engl J Med (1985) 2.62
Calmodulin is a subunit of nitric oxide synthase from macrophages. J Exp Med (1992) 2.55
Development of Daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus. J Clin Microbiol (2005) 2.53
Ceftazidime-resistant Klebsiella pneumoniae and Escherichia coli bloodstream infection: a case-control and molecular epidemiologic investigation. J Infect Dis (1996) 2.49
Identity and interspecific transfer of gentamicin-resistance plasmids in Staphylococcus aureus and Staphylococcus epidermidis. J Infect Dis (1980) 2.48
Are active microbiological surveillance and subsequent isolation needed to prevent the spread of methicillin-resistant Staphylococcus aureus? Clin Infect Dis (2005) 2.47
Vancomycin-resistant enterococci: why are they here, and where do they come from? Lancet Infect Dis (2001) 2.46
Epidemiology of colonisation of patients and environment with vancomycin-resistant enterococci. Lancet (1996) 2.44
A comparison of the effect of universal use of gloves and gowns with that of glove use alone on acquisition of vancomycin-resistant enterococci in a medical intensive care unit. Ann Intern Med (1996) 2.38
Medical and surgical treatment of parapneumonic effusions : an evidence-based guideline. Chest (2000) 2.36
Role of interferon regulatory factor 1 in induction of nitric oxide synthase. J Exp Med (1994) 2.35
Role of oxygen-dependent mechanisms in antibody-induced lysis of tumor cells by activated macrophages. J Exp Med (1980) 2.25
Modulation of macrophage function by transforming growth factor beta, interleukin-4, and interleukin-10. Ann N Y Acad Sci (1993) 2.20
Evaluation of bacterial survival and phagocyte function with a fluorescence-based microplate assay. Infect Immun (1997) 2.09
Genetically diverse ceftazidime-resistant isolates from a single center: biochemical and genetic characterization of TEM-10 beta-lactamases encoded by different nucleotide sequences. Antimicrob Agents Chemother (1993) 2.03
Antimicrobial resistance rates among aerobic gram-negative bacilli recovered from patients in intensive care units: evaluation of a national postmarketing surveillance program. Clin Infect Dis (1996) 2.03
Acute infectious epiglottitis in adults. Ann Intern Med (1969) 1.97
Peptide methionine sulfoxide reductase from Escherichia coli and Mycobacterium tuberculosis protects bacteria against oxidative damage from reactive nitrogen intermediates. Proc Natl Acad Sci U S A (2001) 1.93
Epidemics of nosocomial urinary tract infection caused by multiply resistant gram-negative bacilli: epidemiology and control. J Infect Dis (1976) 1.92
Alkyl hydroperoxide reductase subunit C (AhpC) protects bacterial and human cells against reactive nitrogen intermediates. Mol Cell (1998) 1.92
Structural and phenotypic varieties of gentamicin resistance plasmids in hospital strains of Staphylococcus aureus and coagulase-negative staphylococci. Antimicrob Agents Chemother (1982) 1.89
Pseudoepidemics in hospital. Lancet (1977) 1.89
Novel triterpenoids suppress inducible nitric oxide synthase (iNOS) and inducible cyclooxygenase (COX-2) in mouse macrophages. Cancer Res (1998) 1.80
Inducible nitric oxide synthase-deficient mice have enhanced leukocyte-endothelium interactions in endotoxemia. FASEB J (1997) 1.80
The high-output nitric oxide pathway: role and regulation. J Leukoc Biol (1994) 1.75
Breast abscess: coagulase-negative staphylococcus as a sole pathogen. Clin Infect Dis (1993) 1.72
Cephaloridine therapy as related to renal function. Antimicrob Agents Chemother (Bethesda) (1965) 1.67
Resistance-transfer factor in Enterobacteriaceae. N Engl J Med (1966) 1.65
Yersinia enterocolitica septicemia with septic arthritis. Arch Intern Med (1976) 1.61
External sources of vancomycin-resistant enterococci for intensive care units. Crit Care Med (1998) 1.59
Hospital outbreaks caused by Pseudomonas aeruginosa: importance of serogroup O11. J Clin Microbiol (1982) 1.58
Role of activated macrophages in antibody-dependent lysis of tumor cells. J Exp Med (1980) 1.58
Interleukin-8. A mitogen and chemoattractant for vascular smooth muscle cells. Circ Res (1994) 1.57
The fluctuation of plasma carotenoid concentrations by phase of the menstrual cycle: a controlled diet study. Am J Clin Nutr (1996) 1.57
Cephalexin therapy as related to renal function. Am J Med Sci (1970) 1.56
Gentamicin-resistant staphylococci as hospital flora: epidemiology and resistance plasmids. J Infect Dis (1982) 1.54
Association of infection caused by Pseudomonas aeruginosa serotype O11 with intravenous abuse of pentazocine mixed with tripelennamine. J Clin Microbiol (1984) 1.54
AIDS-related Pneumocystis carinii pneumonia in older patients. J Gen Intern Med (1996) 1.54
Stability of vancomycin-resistant enterococcal genotypes isolated from long-term-colonized patients. J Infect Dis (1998) 1.53
Variations in intensive care unit utilization for patients with human immunodeficiency virus-related Pneumocystis carinii pneumonia: importance of hospital characteristics and geographic location. Crit Care Med (1998) 1.52
A novel antioxidant gene from Mycobacterium tuberculosis. J Exp Med (1997) 1.52
Patients' endogenous flora as the source of "nosocomial" Enterobacter in cardiac surgery. J Infect Dis (1987) 1.49
Relationship between procedures and health insurance for critically ill patients with Pneumocystis carinii pneumonia. Am J Respir Crit Care Med (1995) 1.48
Epidemiology of endemic Pseudomonas aeruginosa: why infection control efforts have failed. J Infect Dis (1984) 1.46
Infections due to gentamicin-resistant Staphylococcus aureus strain in a nursery for neonatal infants. Antimicrob Agents Chemother (1978) 1.45
Mechanism of suppression of nitric oxide synthase expression by interleukin-4 in primary mouse macrophages. J Leukoc Biol (1994) 1.45
Adhesion-dependent protein tyrosine phosphorylation in neutrophils treated with tumor necrosis factor. J Cell Biol (1993) 1.45
Diphtheria in the United States, 1971-81. Am J Public Health (1985) 1.44
Inactivation of nitric oxide synthase after prolonged incubation of mouse macrophages with IFN-gamma and bacterial lipopolysaccharide. J Immunol (1994) 1.43
Pyogenic sacroiliitis. Am J Med (1980) 1.43
Role of the tyrosine kinase pyk2 in the integrin-dependent activation of human neutrophils by TNF. J Clin Invest (1999) 1.40